Climb Bio CLYM
NASDAQ CLYM
$10.89 -0.18 (-1.63%)
As of: Oct 2, 2026 · 3:51 PM EDT

Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026)

Updated

Climb Bio (CLYM) recorded Depreciation & Amortization (CF) of $33,000 in Q2 2026, down 13.2% from $38,000 a year earlier and down 13.2% from the prior quarter.

Analysis

Climb Bio (CLYM) Depreciation & Amortization (CF) (2025 - 2026) Analysis & Trends

On a TTM basis, Climb Bio's Depreciation & Amortization (CF) came in at $130,000 as of Jun 30, 2026, up 242.1% year-over-year; for FY2025, it was $97,000.

  • Quarterly Depreciation & Amortization (CF) has ranged from $29,000 in Q3 2025 to $38,000 in Q1 2026 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $38,000 (Q1 2026), $30,000 (Q4 2025) and $29,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 1.96 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 194.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 599.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 1.93 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 1.11 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 98.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 1.62 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 56.50 Mn
10 Climb Bio 873.49 Mn 873.49 Mn - 33,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 33,000.00
Mar 31, 2026 38,000.00
Dec 31, 2025 30,000.00
Sep 30, 2025 29,000.00
Jun 30, 2025 38,000.00
API Access

Climb Bio Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=CLYM&period=max&api_key=YOUR_API_KEY